Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Dimethyl fumarate protects pancreatic islet cells and non-endocrine tissue in L-arginine-induced chronic pancreatitis.
Hematopoietic stem cell transplantation for MS: extraordinary evidence still needed.
Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29 000 subjects.
Timing of birth and risk of multiple sclerosis: population based study.
Interferon-beta1b for the treatment of multiple sclerosis.
Brain-gut axis and pentadecapeptide BPC 157. Theoretical and practical implications.
Association Between Sleep Problems and Perceived Cognitive Dysfunction Over 12 Months in Individuals with Multiple Sclerosis.
Autoimmune myelopathies.
Switching patients at high risk of PML from natalizumab to another disease-modifying therapy.
Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study.
Selective Chemical Modulation of Gene Transcription Favors Oligodendrocyte Lineage Progression.
Neurons and astroglia govern microglial endotoxin tolerance through macrophage colony-stimulating factor receptor-mediated ERK1/2 signals.
[Prevalence of multiple sclerosis in the Region of Murcia].
Rituximab for relapsing-remitting multiple sclerosis.
Immunopathology: autoimmune glial diseases and differentiation from multiple sclerosis.
Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis.
Effects of dimethyl fumarate on lymphocyte subsets.
New data from Phase 3 studies provide additional evidence supporting treatment effect for oral BG-12 (dimethyl fumarate) in multiple sclerosis
Inosine, an Endogenous Purine Nucleoside, Suppresses Immune Responses and Protects Mice from Experimental Autoimmune Encephalomyelitis: a Role for A2A Adenosine Receptor.
Effects of Delayed-Release Dimethyl Fumarate (DMF) on Health-Related Quality of Life in Patients With Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies.
Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica.
B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells.
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.
Atypical facial pain in multiple sclerosis caused by spinal cord seizures: a case report and review of the literature.
Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study.

Pages